New Drug Development Business
KIYAN PHARMA Co., Ltd. is developing groundbreaking pharmaceuticals using 5-aminolevulinic acid (5-ALA). This initiative is being advanced through close cooperation with domestic and international private companies and public institutions, focusing on developing new drugs for infectious diseases and lifestyle-related diseases.
In particular, collaborative frameworks are being established with research institutions in emerging countries, and future developments are anticipated.
Potential of 5-ALA as a Pharmaceutical
5-ALA plays an important role in mitochondrial function, and mitochondrial dysfunction is believed to cause various diseases. Clinical research on other diseases caused by mitochondrial dysfunction and metabolic disorders is also anticipated.
Licensing Business
In the licensing business, the data obtained from clinical trials conducted by our company are provided to domestic and international pharmaceutical companies for use, expanding this business model.
KIYAN PHARMA Business Overview
5-ALA is manufactured to meet the quality requirements of pharmaceuticals, health foods, cosmetics, fertilizers, and animal feed.
The Fukuroi plant is expanding contract manufacturing for pharmaceutical APIs and intermediates in addition to 5-ALA production.
Supplements and skincare products containing 5-ALA support consumers’ beauty and health.
Products utilizing 5-ALA contribute to animal health and plant growth.
